medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2023, Number 4

<< Back Next >>

Rev Latin Infect Pediatr 2023; 36 (4)

Clinical, epidemiological characteristics, diagnosis and treatment established in invasive fungal infection in pediatric patients: case series

Pérez ÁHF, Ramírez CARRM, Martínez BME

Language: Spanish
References: 17
Page: 173-179
PDF size: 226.31 Kb.


ABSTRACT

Introduction: invasive fungal infection (IFI) represents a public health problem in immunocompromised and critically ill patients, with considerable mortality. Objective: to describe the clinical, epidemiological, diagnostic and treatment characteristics in patients with confirmed invasive fungal infection. Material and methods: a case series study was carried out, by reviewing the records of previously healthy pediatric patients, with confirmed invasive fungal infection, from January to December 2022. Information was obtained on sociodemographic, clinical, laboratory variables, cultures, mucormycosis, treatment (antibiotic and antifungal) and complications during the hospital stay. In the statistical analysis, percentages, measures of central tendency and dispersion were obtained according to the Shapiro-Wilk normality test. Results: nine patients with invasive fungal infection were analyzed, 55.6% children, mean age 8.6 ± 4.8 years, 91.6% with acute lymphoblastic leukemia type B (50%), 25% with infiltration to the central nervous system, in chemotherapy phase from induction to remission. (88.9%), with jugular central venous catheter (44.4%), mean 29.9 ± 21.6 days-catheter, 88.9% with fever, severe neutropenia and neutropenic colitis, systemic inflammatory response syndrome 55.6%. In blood cultures C. parapsilosis (11.1%) was reported and in mycological culture Aspergillus fumigatus (33.3%), Mucor spp (22.2%) and Fusarium oxysporum (11.1%), 22.2% with fungomas, using amphotericin B (100%), caspofungin (44.4%) and voriconazole (33.3%), with 44.5% mortality. Conclusions: in immunocompromised or critically ill patients, it is essential to perform strict follow-up to timely identify opportunistic infections and reduce complications.


REFERENCES

  1. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK et al. Outpatient management of fever and neutropenia in adults treated for malignancy: american society of clinical oncology and infectious diseases society of america clinical practice guideline update. J Clin Oncol. 2018; 36 (14): 1443-1453.

  2. Martín A, Soler-Palacn P, Espaol T, Dapena JL, Urrutia E, Navarro M et al. Spanish paediatric infectious diseases society consensus document on the treatment of fungal infections based on the immune response. An Pediatr. 2010; 73 (6): 362-362.

  3. González-Vicent M, Ramos-Amador JT. La infección fúngica en el paciente pediátrico inmunodeprimido. Rev Iberoam Micol. 2021; 38: 75-83.

  4. Spallone A, Schwartz IS. Emerging Fungal Infections. Infect Dis Clin N Am. 2021; 35 (2): 261-277.

  5. Rodríguez-Dorantes LA, Gómez-Toscano V, Rodríguez-Jurado RR, Díaz-García L. Enfermedad fúngica invasiva por hongos fi lamentosos: perfil clínico-epidemiológico y de respuesta farmacológica en un Hospital de Tercer Nivel en México. Rev Latin Infect Pediatr. 2018; 31 (4): 152-158.

  6. Pathakumari B, Liang G, Liu W. Immune defence to invasive fungal infections: a comprehensive review. Biomed Pharmacother. 2020; 130: 110550.

  7. Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016; 27 (5): 111-118.

  8. Von Lilienfeld TM, Wagener J, Einsele H, Cornely OA, Kurzai O. Invasive fungal infection. New treatments to meet new challenges. Dtsch Arztebl Int. 2019; 116: 271-278.

  9. Lehrnbecher T, Fisher BT, Phillips B, Beauchemin M, Carlesse F, Castagnola E et al. Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. J Clin Oncol. 2020; 38 (27): 3205-3217.

  10. Sanguinetti M, Posteraro B, Beigelman AC, Lamoth F, Dunet V, Slavin M et al. Diagnosis and treatment of invasive fungal infections: looking ahead. J Antimicrob Chemother 2019; 74 (2): 27-37.

  11. Seth R, Xess I, Jana M. Diagnosis of invasive fungal infections in children. Indian Pediatr. 2019; 56 (3): 229-236.

  12. Hodgman EI, Compton J, Qureshi FG, Murphy JT. Diagnosis of invasive fungal infection among pediatric oncology patients. J Pediatr Hematol Oncol. 2019; 41 (8): 596-600.

  13. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J of Med Microbiol. 2006; 55: 809-818.

  14. Wattier RL, Dvorak CC, Hoffman JA, Brozovich AA, Bin-Hussain I, Groll AH et al. A Prospective, international cohort study of invasive mold infections in children. J Pediatric Infect Dis Soc. 2015; (4): 313-322.

  15. Lyman G. Perspectives in febrile neutropenia. AJMC. 2017; 116 (14): 9-13.

  16. Georgiadou SP, Pongas G, Fitzgerald NE, Lewis RE, Rytting M, Marom EM et al. Invasive mold infections in pediatric cancer patients reflect heterogeneity in etiology, presentation, and outcome: a 10-year, single-institution, retrospective study. J Pediatric Infect Dis Soc. 2012; 1 (2): 125-135.

  17. Méndez-Tovar LJ, Mejía-Mercado JA, Manzano-Gayosso P, Hernández-Hernández F, López-Martínez R, Silva González I. Frecuencia de micosis invasivas en un hospital mexicano de alta especialidad. Experiencia de 21 años. Rev Med Inst Mex Seguro Soc. 2016; 54 (5): 581-587.




2020     |     www.medigraphic.com